Japanese manufacturer of generic (off-patent) pharmaceutical drugs sold to hospitals and pharmacies.
Japanese manufacturer of generic (off-patent) pharmaceutical drugs sold to hospitals and pharmacies.
Prices for its drugs are set on the government's reimbursement list and cut regularly, so it competes on volume gained when doctors and pharmacies switch patients to generics and on production cost, since the selling price is not negotiable. It also makes drugs on contract for other pharma companies.
In one line: Japan's Teva / Viatris.
Moat: none (scale, regulatory licence). Generic drug maker competing on cost and government-mandated price cuts, with little product differentiation.
Headquarters: Osaka, Japan · Founded: 1951 · Employees: 4,923
Size Towa Pharmaceutical (4553.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 726th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,390 on 18 Nov 2026.
Performance Over six months the shares fell 10.3%, against -11.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 7.1% over the last twelve months (peer median +3.9%); the operating margin is 8.9% (peer median 7.4%).
Valuation It trades at 7.7× forward earnings against a peer median of 18.3× (3rd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.2 points below its cost of capital (5.0% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥285B | ¥274B | ¥260B | ¥228B | ¥209B |
| Revenue growth | — | +5% | +14% | +9% | — |
| Gross profit | ¥103B | ¥99.1B | ¥94.7B | ¥81.4B | ¥72.7B |
| EBITDA | ¥47.7B | ¥45.9B | ¥43.3B | ¥35.5B | ¥24.9B |
| Net income | ¥3.90B | ¥5.25B | ¥19.0B | ¥16.2B | ¥2.20B |
| Free cash flow | ¥10.9B | ¥8.15B | -¥5.33B | -¥29.6B | -¥26.2B |
| Capital expenditure | ¥17.7B | ¥24.1B | ¥31.2B | ¥39.3B | ¥30.5B |
| Total debt | ¥230B | ¥227B | ¥231B | ¥202B | ¥162B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Towa Pharmaceutical 4553.T | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% |
| SAWAI 4887.T | $1.01B | -18% | +2% | 9% | 12.0× | n/a |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4553.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.9% | -9.8% | 10th highest of 21 |
| 6-month return | -10.3% | -11.9% | 9th highest of 21 |
| Distance from 52-week high | -24.5% | -32.4% | 6th highest of 21 |
| Revenue growth (TTM) | +7.1% | +3.9% | 9th highest of 19 |
| Operating margin | 8.9% | 7.4% | 9th highest of 20 |
| Forward P/E | 7.7× | 18.3× | 3rd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -0.3% | 2.5% | 5th least demanding of 14 |
| Growth delivered (Del g) | +12.1% | +3.5% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -12.4 pp | +0.5 pp | 3rd least demanding of 14 |
| ROIC minus cost of capital | -0.2 pp | +0.1 pp | 10th highest of 19 |
| EV / EBITDA | 7.1× | 16.3× | cheapest of 5 |
| Net debt / EBITDA | 3.5× | -1.3× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |